The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy

Journal of Infectious Diseases

Volumn 210, Issue 3, 2014, Pages 383-391

  Byakwaga, Helen ^a,b   Boum II, Yap ^b,c   Huang, Yong ^d   Muzoora, Conrad ^b   Kembabazi, Annet ^b   Weiser, Sheri D ^d   Bennett, John ^a   Cao, Huyen ^e   Haberer, Jessica E ^f,g   Deeks, Steven G ^d   Bangsberg, David R ^g,h,i   McCune, Joseph M ^d   Martin, Jeffrey N ^a   Hunt, Peter W ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^c EPICENTRE   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ MIT and Harvard   (United States)

Author keywords

Antiretroviral therapy; HIV; Indoleamine 2,3 dioxygenase 1; Kynurenine; Mortality; Tryptophan; Uganda

Indexed keywords

ANTIRETROVIRUS AGENT; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; LIPOPOLYSACCHARIDE; TRYPTOPHAN; VIRUS RNA; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 17; UNCLASSIFIED DRUG;

ADULT; AGE; AMINO ACID BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CATABOLISM; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CORRELATIONAL STUDY; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEX DIFFERENCE; SIGNAL TRANSDUCTION; UGANDAN; VIRUS INHIBITION; VIRUS LOAD; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CONVALESCENCE; CYTOKINE PRODUCTION; LYMPHOCYTE PROLIFERATION; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TRYPTOPHAN METABOLISM; UGANDA;

ANTIRETROVIRAL THERAPY; HIV; INDOLEAMINE 2,3-DIOXYGENASE-1; KYNURENINE; MORTALITY; TRYPTOPHAN; UGANDA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; KYNURENINE; MALE; TRYPTOPHAN; UGANDA;

EID: 84904314814     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu115     Document Type: Article

References (38)

1. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9:139-47.
2. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-74.
3. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5:2516-22.
4. Grant RS, Naif H, Thuruthyil SJ, et al. Induction of indoleamine 2,3- dioxygenase in primary human macrophages by HIV-1. Redox Rep 2000; 5:105-7.
5. Sardar AM, Reynolds GP. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett 1995; 187:9-12.
6. Gold AB, Herrmann N, Swardfager W, et al. The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation 2011; 8:17.
7. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 1999; 467:133-8.
8. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res 2005; 7:103-23.
9. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196:459-68.
10. Boasso A, Herbeuval JP, Hardy AW, et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 2007; 109:3351-9.
11. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
12. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-9.
13. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32ra36.
14. Klatt NR, Estes JD, Sun X, et al. Loss of mucosal CD103+ DCs and IL- 17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol 2012.
15. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202:723-33.
16. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-85.
17. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIVinfected patients on long-term highly active antiretroviral therapy. AIDS 2008; 22:2035-8.
18. Jenabian MA, Patel M, Kema I, et al. Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One 2013; 8:e78146.
19. Hunt PW. Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS 2010; 5:189-93.
20. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91.
21. Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem 1998; 44:858-62.
22. Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol 2002; 104:242-7.
23. Heyes MP, Brew BJ, Saito K, et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol 1992; 40:71-80.
24. Sardar AM, Bell JE, Reynolds GP. Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients. J Neurochem 1995; 64:932-5.
25. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2005; 2:16.
26. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004; 37:684-7.
27. Pertovaara M, Raitala A, Lehtimaki T, et al. Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Dev 2006; 127:497-9.
28. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011; 25:2123-31.
29. Martinez P, TsaiAC,Muzoora C, et al. Reversal of the kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIVinfected Ugandans. J Acquir Immune Defic Syndr 2013; 65:456-62.
30. Huang Y, Louie A, Yang Q, et al. A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients. Bioanalysis 2013; 5:1397-407.
31. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
32. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor- mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15:955-9.
33. Hunt P, Rodriguez B, Shive C, et al. Gut epithelial barrier dysfunction, inflammation, and coagulation predict higher mortality during treated HIV/AIDS [abstract 278]. In: Program and abstracts from the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
34. Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M. Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand J Immunol 2005; 61:387-90.
35. Said EA, Dupuy FP, Trautmann L, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010; 16:452-9.
36. PakkerNG, NotermansDW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
37. Volgraf M, Lumb JP, Brastianos HC, et al. Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol 2008; 4:535-7.
38. Koblish HK, Hansbury MJ, Bowman KJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010; 9:489-98.